Tyrosine protein kinase inhibition and cancer.
The various aspects of the research on tyrosine protein kinase inhibition and its connections with cancer are presented. The emphasis was made on the theoretical low toxic side effects of specific tyrosine protein kinase inhibitors. Particularly, the strategy of finding peptidic substrate-derived inhibitors or modulators is discussed, with an almost complete compendium of the tyrosine protein kinase peptidic substrates published so far. A series of data has been gathered that may serve as a basis for the discovery of selective and specific tyrosine protein kinase inhibitors by screening on molecular and cellular models. The potential of SH2 domain-interfering agents are also presented as a promising route to new anticancer compounds.
Institut de Recherches SERVIER, Département de Chimie des Peptides, Suresnes, France.
J A
JA
Boutin
D000595:Amino Acid Sequence; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D011480:Protease Inhibitors / Q000378:metabolism / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013379:Substrate Specificity
D011480:Protease Inhibitors; D011505:Protein-Tyrosine Kinases